Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业关于分公司收到碳酸司维拉姆干混悬剂受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding the receipt of an acceptance notice from the National Medical Products Administration for a drug registration application. It details the drug name, registration acceptance, and potential impact on the company. The document is short (742 characters) and serves as an official announcement of a regulatory event related to drug registration, not a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-05-15 Chinese
金陵药业股份有限公司关于公司董事辞任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Zhang Qunhong, from the board and related committees. It includes details about the resignation, compliance with company law, and the impact on the board's composition. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the resignation notice. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-05-07 Chinese
金陵药业股份有限公司关于公司及子公司使用闲置自有资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase wealth management products. It details amounts, dates, and types of financial products purchased, risk disclosures, and risk control measures. The document is a specific update on financing activities related to cash management and investment of idle funds, not a full financial report or earnings release. It is not an annual or interim report, nor a regulatory certification or legal proceeding. The content fits best under Capital/Financing Update (CAP) as it provides detailed information on the company's financing and investment activities with idle funds.
2025-04-27 Chinese
关于同一控制下企业合并追溯调整财务数据的公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from Jinling Pharmaceutical Co., Ltd. regarding retrospective adjustments to financial data due to a business combination under common control. It includes extensive financial data adjustments for the first quarter of 2024, including income statement and cash flow statement figures, and explanations referencing relevant accounting standards (Chinese GAAP). The document also contains opinions from the board of directors, audit committee, and supervisory board approving the adjustments. The content is focused on financial data restatement and compliance with accounting standards, not a full annual or interim report, nor a simple announcement of a report. It is not a certification or a brief announcement but a substantive financial disclosure related to audit and accounting adjustments. This fits best with the category of Audit Report / Information (AR), which covers standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document length (over 14,000 characters) and detailed financial data support this classification with high confidence. Q1 2024
2025-04-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Jinling Pharmaceutical Co., Ltd. It details the convening and resolutions passed at the 17th meeting of the 9th board, including approval of retrospective financial data adjustments, the 2024 Sustainability Report, and the 2025 Q1 report. The document states that the detailed reports are published elsewhere (on designated newspapers and websites) and provides voting results. The document itself is short (1079 characters) and serves as an announcement of board decisions and references to other reports rather than containing the full reports or detailed financial data. This fits the category of Board/Management Information (MANG), as it announces board meeting resolutions and decisions. It is not the full quarterly report (IR) or sustainability report (SR), nor is it a report publication announcement (RPA) because it contains substantive board meeting details and resolutions, not just a notice of report availability.
2025-04-27 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年第一季度报告' which translates to '2025 First Quarter Report'. It contains detailed financial data including income, net profit, cash flow, and balance sheet items for the first quarter period ending March 31, 2025. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.